Image Ben Hargreaves Digital Digital health: the new normal? Personalised and tailored healthcare that utilises patient’s data is rapidly becoming a reality. Views & Analysis The power of self-management to target gaps in chronic disea... The time of healthcare professionals is limited, but systems often rely on them as the principal means to help patients with chronic diseases. Views & Analysis GSK continues campaign for greater adult immunisation covera... The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. Views & Analysis Osteoporosis treatment options - down to the bare bones It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease. Load more results
Digital Digital health: the new normal? Personalised and tailored healthcare that utilises patient’s data is rapidly becoming a reality.
Views & Analysis The power of self-management to target gaps in chronic disea... The time of healthcare professionals is limited, but systems often rely on them as the principal means to help patients with chronic diseases.
Views & Analysis GSK continues campaign for greater adult immunisation covera... The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this.
Views & Analysis Osteoporosis treatment options - down to the bare bones It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
